Recorded: Access recorded version, only for one participant unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
Corporate Recorded: Access recorded version, Any number of participants unlimited viewing for 6 months ( Access information will be emailed 24 hours after the completion of live webinar)
One of our most popular webinars, continuously updated with the latest U.S. FDA and Eurpean Union requirements.
One of our most popular webinars, continuously updated with the latest U.S. FDA and Eurpean Union requirements. Now expanded to a six-hour format. As U.S. companies go global, they must meet different product design documentation.
The cGMPs mandate Design Control and the Design History File (DHF). In order to sell globally, the EU's CE-marking documentation is a requirement - the Technical FiIe or Design Dossier under the old MDD, and the Technical Documentation requirements of the new MDR. Currently they serve differnt purposes, support different goals, but the TD File is moving in the direction of the DHF.
And the DHF is adapting to some of the features of the TDFile. And how / where do the DMR and DHR fit? Being aware of the similarities and differences in the files and their individual documents can further concurrent development and/or updates to both.
Why you should Attend: This webinar will examine the existing and proposed requiements for the U.S. FDA's DHF - including its derivitive documents, the DMR and DHR. It will consider the European Union's new MDR Technical Documentation requirements, which replace the old Technical File / Design Dossier.
It will evaluate the documents' differing purposes / goals, as well as the two different device classification schemes, and CE-marking requirements. Required and desirable contents will be discussed.
Also considered: Areas requiring frequent re-evaluation / update; Similiarities and differences; Future trends; Typical DHF Table of Contents; Technical Documentation Table of Contents; The importance and usefulness of the new "General Safety and Performance Requirements" (replacing the old "Essential Requirements"); Structure of the "Declaration of Conformity"; self-declaring or N-B reviewed and changes; parallel approaches to development. Finally, the differing approaches to file audits by the FDA and the Notified Body will be discussed.
Agenda: Session 1